Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Revised 2014 Katagiri Score

A 0-10 additive prognostic score for newly detected skeletal metastases.

Evidence-based context for fast calculator use

Purpose:
Reproduce the source-defined revised 2014 prognostic grouping and historical cohort outcome rows.
Population:
Newly detected symptomatic skeletal metastases assessed before treatment of that presentation.
Factors:
Primary tumor category, Visceral/cerebral disease, Laboratory category, ECOG, Previous chemotherapy, Skeletal burden
Reference:
Katagiri H, et al. Cancer Med. 2014;3(5):1359-1367. DOI: 10.1002/cam4.292.
HomeRevised 2014 Katagiri Score
Pin your most used calculators here by clicking the star in the dropdown.

Revised 2014 Katagiri Score

Clinical Context & Background

This calculator implements the revised Katagiri et al. 2014 prognostic scoring system for patients with newly detected symptomatic skeletal metastases before treatment of that presentation. It asks only for the six scoring inputs; confirmation and timing are stated as eligibility guidance instead of repeated questions. It explicitly excludes the original 2005 score.
Primary tumors are grouped by the source-defined growth and treatment-sensitivity categories. Visceral or cerebral disease distinguishes nodular metastases from pleural, peritoneal, or leptomeningeal dissemination. Laboratory status distinguishes abnormal findings from critical findings, which take precedence. ECOG 0-2 scores zero and ECOG 3-4 scores one.
The displayed 6-, 12-, and 24-month percentages are Kaplan-Meier estimates from a historical single-center cohort and are not individualized probabilities. Confirmed asymptomatic disease can be calculated only with an outside-derivation warning. Unconfirmed disease and assessment after treatment return Not applicable. The score supports multidisciplinary prognostic assessment and does not independently select treatment.
Primary Source EvidenceKatagiri H, Okada R, Takagi T, et al. New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med. 2014;3(5):1359-1367. DOI: 10.1002/cam4.292.
Formula Logic
Revised 2014 Katagiri score = primary tumor category (0, 2, or 3) + visceral/cerebral metastasis category (0, 1, or 2) + laboratory category (0, 1, or 2) + ECOG 3-4 (1) + previous chemotherapy (1) + multiple skeletal metastases (1); total 0-10.

Reference Data

ScoreGroup6-month survival12-month survival24-month survival
0-3Low98.1%91.4%77.8%
4-6Intermediate74.0%49.3%27.6%
7-10High26.9%6.0%2.1%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • At initial detection of confirmed skeletal metastases, before treatment of that presentation.
  • Use the source-defined primary, visceral/cerebral, laboratory, ECOG, chemotherapy-history, and skeletal-burden categories.

How To Interpret

  • Scores 0-3, 4-6, and 7-10 map to low, intermediate, and high prognostic groups.
  • Displayed survival estimates are historical cohort Kaplan-Meier estimates, not individualized probabilities.

What To Do Next

  • Document the exact categories and assessment timing.
  • Integrate the score with oncology, orthopedic, radiation-oncology, palliative-care, imaging, comorbidity, and patient-preference assessment.

Limitations

  • Historical single-center systemic-treatment era with few surgical patients and small samples for some cancers.
  • The derivation cohort had newly detected symptomatic disease; asymptomatic use is outside the derivation presentation.
  • Not for unconfirmed disease or post-treatment reassessment and not an autonomous treatment-selection tool.

Validated Population

Newly detected symptomatic skeletal metastases in the Katagiri et al. 2014 single-center cohort.

Source example

Moderate primary, nodular metastasis, abnormal laboratory data, ECOG 3-4, previous chemotherapy, and multiple skeletal metastases total 7 points.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Three source-backed Katagiri cases passed through visible production controls at scores 0, 5, and 10 across all prognostic groups.
    • No unexpected N/A, literal undefined value, stale control, or browser-console error was observed.
    Download latest production check (Excel)

    Case-level evidence is retained in validation/browser-revalidation/katagiri-bone-met-2026-08-03.json.

  2. : Production browser validation

    • Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
    • Overall browser status: failed-console. medium: Production emitted minified React error #418 during route loads/reloads used by this run.
    • Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.

    Case-level production evidence is retained in validation/browser-production/katagiri-bone-met.json.

  3. : Input workflow simplified and revalidated

    • Reduced the public form to result-, branch-, unit-, and applicability-changing inputs; removed or consolidated non-scoring, administrative, and duplicate questions.
    • Preserved the verified calculation or report-interpretation logic, thresholds, model version, component logic, and supported result pathways behind strict deterministic adapters.
    • Passed the calculator-specific regression audit, adapter-parity and malformed-input checks, the 144-calculator input-quality audit, and the 43-calculator entry-burden audit.

  4. : Full validation test

    • 544/544 source-model, exhaustive valid-state, UI, laboratory-boundary, malformed-input, applicability, trace, registry, report, history, and isolation checks passed.
    • This verifies implementation of the revised 2014 model, not independent clinical validation, an individualized survival probability, or a treatment recommendation.

  5. : Calculation and input-contract correction

    • Locked the calculator to the revised 2014 model and restored source-defined primary-tumor, visceral/cerebral, laboratory, ECOG, chemotherapy, and skeletal-burden rules.
    • Corrected RCC, nodular versus disseminated disease, the critical laboratory tier, ECOG 4, and exact group outcomes.
    • Removed favorable defaults, permissive point summing, unsupported survival ranges, and autonomous treatment directives; added explicit population and timing gates.

    Included in the current validation report.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Related Tools

Bauer Score (Bone Mets)Tokuhashi Score Calculator — Spine Metastases Surgical PrognosisTomita Score (Spine Mets)

Frequently Asked Questions

Is renal cell carcinoma a slow primary in the revised Katagiri score?

No. Renal cell carcinoma is in the source-defined moderate category and contributes two points.

How are laboratory findings classified?

Critical findings contribute two points and override abnormal findings. The public form uses the resulting source category and displays all six raw thresholds.

Does a high score determine treatment?

No. It is prognostic stratification from a historical cohort and must be interpreted with multidisciplinary assessment.

Evidence-based oncology decision support. Verify with clinical guidelines.